Nanobiotherapeutic Based Blood Substitutes

About

Thomas Ming Swi Chang OC MD CM PhD FRCPC FRSC Director Artificial Cells & Organs Research Centre Professor Emeritus of Physiology Medicine and Biomedical Engineering Faculty of Medicine McGill University Montreal Quebec Canada; Director Chang Artificial Cell Translation Research Institute Faculty of Medicine Shenzhen University China; Director Academician TMS Chang Research station Shantou University Medical School China; Honorary Professors at Peking Union Medical College; Blood Transfusion Institute of the Chinese Academy Medical Sciences and Nankai University; Honorary President International Society of Artificial Cells Blood Substitutes & Biotechnology. Editor in Chief Artificial Cells Nanomedicine & Biotechnology an international Journal Editor in Chief Regenerative Medicine Artificial Cells & Nanomedicine Book Series. He invented the first artificial red blood cell during his BSc at McGill in 1957. There was no initial interest. He persisted while studying for his MD then PhD (Chang Science 1964 Nature 1971). By breaking out of the box of reproducing biological cells he prepares artificial cells with (1) DIMENSIONS: from macro micro nano to soluble nanobiotechnological complexes. (2) CONTENTS; biological cell contents cells stem cells vaccines magnetic material adsorbents (3) MEMBRANES: biological and polymeric with variations in permeability biodegradability biocompatibility targeting abilities etc. His 2019 review https://www.tandfonline.com/doi/full/10.1080/21691401.2019.1577885 shows that ARTIFICIAL CELL has evolved into nanomedicine biotherapeutics blood substitutes drug delivery enzyme/gene therapy cancer therapy cell/stem cell therapy nanoparticles liposomes bioencapsulation synthetic cells cell encapsulation/scaffold biosorbent/immunosorbent hemoperfusion/plasmapheresis regenerative medicine encapsulated microbe nanobiotechnology nanotechnology. Jonathan S Jahr MD DABA FASA is Professor Emeritus of Anesthesiology and Perioperative Medicine at UCLA. He has distinguished himself by authoring or co-authoring over 200 publications co-editing a textbook and serving on multiple editorial boards of major journals and as a reviewer for the NIH and FDA. His leadership in oxygen therapeutics from managing and publishing major clinical trials to understanding the impact of hemoglobin based oxygen carriers on coagulation have created value for the entire scientific community and helped foster future products to be developed and tested. As lead investigator in the Hemopure trial in elective orthopedic patients he presented the largest non-trauma database of subjects receiving an HBOC and combined with the studies of Hemopure PolyHeme and Hemosol allowed for post-marketing study of Hemopure in South Africa. His animal studies with Oxyglobin in hemodynamics oxygen delivery intravital microscopy laboratory interference coagulation added to the knowledge base for this FDA and EU approved veterinary product for canine anemia. Additionally his contributions to major acute pain and other anesthetic medications have bettered patient's care and lives. Hiromi Sakai received PhD (DEng) in polymer chemistry in 1994 from Waseda Univ. Tokyo with a thesis entitled Hemoglobin-vesicles (HbV) as a molecular assembly (Supervisor late Prof. E Tsuchida) and since then he has continuously studied the production safety and efficacy evaluations of HbV. In 1996-1998 he studied at Dept. Bioengineering UC San Diego (Supervisor Prof. M Intaglietta) and evaluated the microvascular responses to HbV injection. After coming back to Tokyo he studied improvement of the stabilization and biocompatibility of HbV and evaluated its safety and efficacy by animal experiments. In 2006 he received PhD (DMedSci) from Keio Univ. School of Medicine (Supervisor Prof. K Kobayashi). Dr Sakai was a Lecturer and an Associate Professor at Research Institute for Sci.&Eng. Waseda Univ. in 1998-2009 and PI at Waseda Bioscience Research Institute in Singapore in 2009-2013. From 2013 he has been the Professor of Chemistry Nara Medical University Kashihara Japan. He is the chief investigator of the artificial red cells project aiming at clinical applications which has been supported by Ministry of Health Labour and Welfare Japan (MHLW) and the Japan Agency for Medical Research and Development (AMED). From 2019 he is the fourth president of the Society of blood Substitutes Japan (SBSJ).